Cheah P L, Looi L M, Ng M H, Sivanesaratnam V
Department of Pathology, University of Malaya Medical Centre, 50603 Kuala Lumpur, Malaysia.
J Clin Pathol. 2002 Jan;55(1):22-6. doi: 10.1136/jcp.55.1.22.
Telomerase activity was studied in invasive uterine cervical carcinoma to assess whether it was activated during cervical malignant transformation and to look for a possible association with human papillomavirus (HPV) infection in a set of Malaysian patients.
Histologically confirmed invasive cervical carcinoma and benign cervices were assayed for telomerase activity using a commercial telomerase polymerase chain reaction (PCR) enzyme linked immunosorbent assay kit. The same cases were subjected to PCR detection of HPV using type specific (HPV types 6b, 11, 16, and 18) followed by L1 open reading frame (ORF) consensus primers.
HPV was detected in 18 (13 HPV-16, one HPV-6b, four only L1 ORF) of 20 invasive cervical carcinoma and one (only L1 ORF) of 19 benign cervices. Raised telomerase activity (A(450 nm) > 0.215) was detected in 11 cervical carcinomas, with A(450 nm) ranging between 0.238 and 21.790 (mean, 3.952) in positive squamous carcinomas, whereas A(450 nm) was only 0.222 in the one positive adenosquamous carcinoma. Five of 11 cervical carcinomas in stage I, three of six in stage II, both in stage III, and the only case in stage IV showed telomerase activation. Increased telomerase activity was noted in five of the 12 lymph node negative, five of the seven lymph node status unknown cases, and the one case with presumed lymph node metastasis. Ten of 18 HPV positive and one of two HPV negative cervical carcinomas showed telomerase upregulation.
Telomerase is activated in invasive cervical carcinoma. Although larger studies are needed, there seems to be no clear association between telomerase upregulation and HPV status, although there is a suggestion of increased telomerase activity in squamous carcinomas and late stage disease.
对浸润性子宫颈癌中的端粒酶活性进行研究，以评估其在宫颈恶性转化过程中是否被激活，并在一组马来西亚患者中寻找其与人类乳头瘤病毒（HPV）感染之间可能存在的关联。
使用商业端粒酶聚合酶链反应（PCR）酶联免疫吸附测定试剂盒，对组织学确诊的浸润性宫颈癌和良性宫颈组织进行端粒酶活性检测。对相同病例采用型特异性（HPV 6b型、11型、16型和18型）PCR检测HPV，随后使用L1开放阅读框（ORF）通用引物。
在20例浸润性宫颈癌中，18例检测到HPV（13例HPV-16型、1例HPV-6b型、4例仅L1 ORF阳性）；在19例良性宫颈组织中，1例检测到HPV（仅L1 ORF阳性）。11例宫颈癌检测到端粒酶活性升高（A（450 nm）>0.215），阳性鳞状细胞癌中A（450 nm）范围为0.238至21.790（平均3.952），而1例阳性腺鳞癌中A（450 nm）仅为0.222。I期11例宫颈癌中的5例、II期6例中的3例、III期的2例以及IV期的唯一1例均显示端粒酶激活。在12例淋巴结阴性的病例中有5例、7例淋巴结状态未知的病例中有5例以及1例推测有淋巴结转移的病例中均观察到端粒酶活性增加。18例HPV阳性宫颈癌中的10例以及2例HPV阴性宫颈癌中的1例显示端粒酶上调。
浸润性宫颈癌中端粒酶被激活。尽管需要更大规模的研究，但端粒酶上调与HPV状态之间似乎没有明确关联，不过鳞状细胞癌和晚期疾病中端粒酶活性有增加的迹象。
